National Health and Family Planning Commission, P.R.China
12
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
50%
6 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Risk Stratification and Minimally Invasive Surgery in Acute ICH Patients
Role: collaborator
The Efficacy of Xuebijing Injection on Sepsis
Role: collaborator
Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals
Role: collaborator
National Study on Autism Spectrum Disorder in China
Role: collaborator
China Registry of Non-disabling Ischemic Cerebrovascular Events
Role: collaborator
The Evaluation and Management of Patients With Acute Chest Pain in China
Role: collaborator
Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients
Role: collaborator
Emtricitabine for Naive Chinese Chronic Hepatitis B Patients
Role: collaborator
Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients
Role: collaborator
Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients
Role: collaborator
Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients
Role: collaborator
Observational Study on Patients With Chronic Hepatitis B
Role: collaborator
All 12 trials loaded